Latest Advances in Lung Cancer Research

The CDC’s 2026 report finds falling lung cancer death rates are the biggest reason U.S. cancer mortality keeps declining after more than 20 years.

A new study found blood changes linked to air pollution exposure show up years before a lung cancer diagnosis.

Patients with ROS1 lung cancer have a new option. On July 22, 2026, the FDA approved zidesamtinib, sold as Jideytro. The maker is Nuvalent, Inc.

New study shows counting smoking years, not cigarette amount, could catch more lung cancers and make screening fairer for veterans.

Drs. Riely and Levy explain the necessity of reflex genomic testing in lung cancer to ensure personalized treatment and better patient outcomes.

Lung cancer kills more people than breast, colon, and cervical cancers combined. Yet it is the cancer we screen for the least. A new study in the Journal of the American Medical Association shows that universal lung cancer screening could change this.

A new NYT report shows that only a small fraction of people who qualify for lung-cancer screening get tested, leaving many early cancers undetected.

A Forbes article warns that few eligible Americans get lung cancer screening the and cancellation of a USPSTF meeting could delay important updates, worsening underuse.

Study of 1,143 lung cancer patients shows improved MET exon 14 mutation detection methods help select better targeted treatments.

Researchers developed RARE-seq, an ultrasensitive blood test detecting cell-free RNA that identifies early-stage lung cancer and monitors treatment resistance.

Chest CT scans used for lung cancer screening can do more than just find early lung cancer. These scans can also detect heart problems and early emphysema, offering a three-in-one health check for people at risk.